HC Wainwright Weighs in on Talphera FY2029 Earnings

Talphera, Inc. (NASDAQ:TLPH) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Talphera in a report released on Tuesday, April 1st. HC Wainwright analyst E. Arce forecasts that the company will post earnings of $0.83 per share for the year. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.64) per share.

Talphera (NASDAQ:TLPH) last posted its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.14.

Several other equities research analysts also recently issued reports on TLPH. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of Talphera in a report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 target price for the company.

Talphera Stock Up 10.0 %

Shares of Talphera stock opened at $0.58 on Thursday. Talphera has a 52 week low of $0.45 and a 52 week high of $1.27. The business has a 50 day moving average price of $0.60 and a 200-day moving average price of $0.71. The company has a market cap of $9.93 million, a PE ratio of -0.84 and a beta of 0.20.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.